NL
DE
ReCognitION, a new 1.3 M€ European project under the leadership of Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon, was kicked-off in Gent. ReCognitION is an acronym for Recognition and Validation of Druggable Targets from the response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks. The project is built on the successful OPTIMISTIC clinical trial. The OPTIMISTIC trial showed a positive effect of lifestyle interventions on the social participation and physical activity of Myotonic Dystrophy patients. In ReCognitION, Radboudumc will work with partners in Gent, Paris, Prague and Ottawa to understand the molecular pathways underlying the response to cognitive behavioural therapy and to identify drugs targeting these pathways that may consolidate or reinforce the effect of cognitive behavioural therapy.
ReCognitION was funded by ZON-MW and similar national funding organisations in Belgium, France, the Czech Republic and Canada under the eRARE program.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
New genetic defect links cell biology and protein glycosylation
10 November 2021 Peter Linders, Dirk Lefeber and Geert van den Bogaart together with international colleagues have recently reported on novel cell biological insights, by identifying a genetic disorder in syntaxin-5 which allowed to unravel a new mechanism regulating intracellular transportation. read more
Miniaturized microfluidic platform for automated epigenetic profiling
6 May 2021 Together with Fluidigm, a US-based company focusing on microfluidics, the team of Hendrik Marks publishes in Genome Research the development of a powerful plug and play ChIP-seq platform for minute amount of cells, such as embryonic specimens or small biopsies. read more
Front cover Human Mutation
21 August 2019The MetaDome web server build to interpret genetic variants based on genetic tolerance and homologous protein domains is featured on the Cover of Human Mutation. MetaDome was developed by Laurens van de Wiel, Coos Baakman, Daan Gilissen, Joris Veltman, Gert Vriend and Christian Gilissen,
read more
TURBO grants for four medical-technical research projects
8 November 2018 Four TURBO grants were awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between Radboudumc and the University of Twente. read more
A low cholesterol level is not a good thing
21 June 2018Research shows that low cholesterol can also be harmful. Researchers from Radboudumc and their Australian and American colleagues discovered a new metabolic defect, producing very low cholesterol levels. This causes brain anomalies, developmental delay, epilepsy and typical facial deformities.
read more
